BioSpace News Archive

Guangzhou XlifeSciences, a partner of GenScript ProBio (GenScript’s CDMO segment) announced that the early phase clinical trial of TAEST16001 project has been started. GenScript ProBio extends congratulations on this. This clinical trial project is China’s first TCR-T project targeted at solid tumor therapy, marking a milesto

The NiSource Charitable Foundation, the charitable foundation supported by NiSource Inc., announced that it has committed to $1 million in donations to provide coronavirus relief support across the company’s seven-state service territory.

As more and more people across the country continue to look for safe and convenient options to pick up daily essentials amidst the COVID-19 pandemic, Walgreens is now offering select products at its more than 7,300 pharmacy drive-thrus nationwide.

During the coronavirus global pandemic, MJH Life Sciences™ is dedicated to delivering credible information and providing support to health care professionals on the front lines by hosting free, accredited webinars across multiple channels.

Quantzig, a global data analytics and advisory firm, that delivers actionable analytics solutions to resolve complex business problems brings to you a comprehensive portfolio of analytics solutions tailored to meet the real world needs of pharma and life sciences companies.

New York-based Aquavit Pharmaceuticals, Inc. (Aquavit), a biotechnology company focused on the development of a first-of-its-kind microchannel drug delivery technology, today announces that the company has filed two patent applications with the United States Patent and Trademark Office.

Pfizer Inc. (NYSE: PFE) today announced the completion of a $1.25 billion ten-year “sustainability” bond paying interest semi-annually of 2.625 percent and maturing April 1, 2030.

Astrotech Corporation (NASDAQ: ASTC), today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale of 873,332 shares of Astrotech’s common stock, at a purchase price of $3.75 per share, in a registered direct offering priced at-the-market under Nasdaq rules

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce today that it closed its previously announced registered direct offering for the purchase and sale of 7,000,000 common shares of the Company (the “Common Shares”) at a purchase price of US$0.17

old Therapeutics, a clinical-stage biopharmaceutical company developing novel anti-cancer therapies, announced that recent developments have suggested the potential utility of its lead drug BOLD-100 as a novel antiviral agent.